ContraVir Pharmaceuticals Inc. (Nasdaq: CTRV) reported preliminary positive data for its CMX157 to treat hepatitis B sending shares of the biopharmaceutical soaring $2.01 to $4.12.
ContraVir reports positive data
October 05, 2015 at 14:15 PM EDT
